A comparison of clinically useful phosphorus binders for patients with chronic kidney failure

Kidney International, Supplement

Volumn 66, Issue 90, 2004, Pages

  Emmett, Michael ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hyperphosphatemia; Phosphorus binders; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALTERNAGEL; ALUMINUM CARBONATE; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ALUMINUM HYDROXYCARBONATE; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SALT; CARBONIC ACID DERIVATIVE; CITRATE CALCIUM; GLUCONIC ACID; LACTIC ACID; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; MAGNESIUM SALT; PHOSPHATE BINDING AGENT; SEVELAMER; SUCRALFATE; UNCLASSIFIED DRUG; ALUMINUM; CALCIUM; INORGANIC SALT; PHOSPHATE; PHOSPHORUS;

ALUMINUM OVERLOAD; BONE DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIALYSIS; DIARRHEA; EXCRETION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; METABOLIC ACIDOSIS; NEUROLOGIC DISEASE; PHOSPHATE INTAKE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; HYPOPHOSPHATEMIA; METABOLISM;

ALUMINUM; CALCIUM; HUMANS; HYPOPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; PHOSPHATES; PHOSPHORUS; SALTS;

EID: 4344638044     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09005.x     Document Type: Review

References (73)

1. WILLETT WC, BUZZARD M: Nature of Variation in Diet in Nutritional Epidemiology, 2nd ed, edited by Willett WC, New York, Oxford University Press, 1998, pp 33-49
2. MARRIOTT WM, ROWLAND J: Phosphate retention as a factor in the production of acidosis in nephritis. Arch Intern Med 18:708, 1916
3. FREEMAN S, FREEMAN WMC: Phosphorous retention in children with chronic renal insufficiency. Am J Dis Child 61:981-1002, 1941
4. PARFITT AM: Soft-tissue calcification in uremia. Arch Intern Med 124:544-556, 1969
5. BRICKER NS, SLATOPOLSKY E, REISS E, AVIOLI LV: Calcium, phosphorous, and bone in renal disease and transplantation. Arch Intern Med 123:543-553, 1969
6. BRICKER NS: On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis." N Engl J Med 286:1093-1099, 1972
7. HOU SH, ZHAO J, ELLMAN CF, et al: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 8:217-224, 1991
8. ZUCCHELLI P, SANTORO A: Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 10:173-178, 1987
9. MUCSI I, HERCZ G, ULDALL R, et al: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404, 1998
10. ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294:184-188, 1976
11. ANDREOLI SP, BERGSTEIN JM, SHERRARD DJ: Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 310:1079-1084, 1984
12. SHEIKH MS, MAGUIRE JA, EMMETT M, et al: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J Clin Invest 83:66-73, 1989
13. RAMIREZ JA, EMMETT M, WHITE MG, et al: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30:753-759, 1986
14. BERLYNE GM, BEN-ARI J, PEST D, et al: Hyperaluminaemia from aluminum resins in renal failure. Lancet 2:494-496, 1970
15. CLARKSON EM, LUCK VA, HYNSON WV, et al: The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances, the serum parathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure. Clin Sci 43:519-531, 1972
16. RUSSO LS, BEALE G, SANDRONI S, BALLINGER WE: Aluminium intoxication in undialysed adults with chronic renal failure. J Neurol Neurosurg Psychiatry 55:697-700, 1992
17. CLARKSON EM, MCDONALD SJ, DE WARDENER HE: The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci 30:425-438, 1966
18. GOLD CH, MORLEY JE, VILJOEN M, et al: Gastric acid secretion and serum gastrin levels in patients with chronic renal failure on regular hemodialysis. Nephron 25:92-95, 1980
19. HARDY P, SECHET A, HOTTELART C, et al: Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 22:569-573, 1998
20. TAN CC, HARDEN PN, RODGER RS, et al: Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant 11:851-853, 1996
21. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S, et al: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
22. SLATOPOLSKY E, WEERTS C, NORWOOD K, et al: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36:897-903, 1989
23. CLARKSON EM, EASTWOOD JB, KOUTSAIMANIS KG, DE WARDENER HE: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int 3:258-263, 1973
24. MACTIER RA, VAN STONE J, COX A, et al: Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 28:222-226, 1987
25. MUHAMMEDI MA, PIRAINO B, RAULT R, et al: Iatrogenic hypercalcemia in hemodialysis patients. Clin Nephrol 36:258-261, 1991
26. EMMETT M, SIRMON MD, KIRKPATRICK WG, et al: Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 17:544-550, 1991
27. MAI ML, EMMETT M, SHEIKH MS, et al: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690-695, 1989
28. DELMEZ JA, TINDIRA CA, WINDUS DW, et al: Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3:96-102, 1992
29. BEN HAMIDA F, EL ESPER I, COMPAGNON M, et al: Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron 63:258-262, 1993
30. CARAVACA F, SANTOS I, CUBERO JJ, et al: Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 60:423-427, 1992
31. SCHAEFER K, SCHEER J, ASMUS G, et al: The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study. Nephrol Dial Transplant 6:170-175, 1991
32. MORINIERE P, DJERAD M, BOUDAILLIEZ B, et al: Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron 60:6-11, 1992
33. MERIC F, YAP P, BIA MJ: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16:459-464, 1990
34. CUSHNER HM, COPLEY JB, LINDBERG JS, FOULKS CJ: Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF. Kidney Int 33:95-99, 1988
35. DUNSTAN CR, EADE YL, EVANS M, et al: The effectiveness of a soluble calcium preparation as a gut phosphate binder. Metabolism 37:815-819, 1988
36. ZIMMERMANN E, WASSMER S, STEUDLE V: Long-term treatment with calcium-alpha-ketoglutarate corrects secondary hyperparathyroidism. Miner Electrolyte Metab 22:196-199, 1996
37. BIRCK R, ZIMMERMANN E, WASSMER S, et al: Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study. Nephrol Dial Transplant 14:1475-1479, 1999
38. LEGENDRE JY, COTE S, PRADEAU D, et al: Efficient phosphate binding using a combination of gluconolactate and carbonate calcium salts. J Clin Pharm Ther 19:233-238, 1994
39. NOLAN CR, CALIFANO JR, BUTZIN CA: Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 38:937-941, 1990
40. SCHILLER LR, SANTA ANA CA, SHEIKH MS, et al: Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320:1110-1113, 1989
41. SECHET A, HARDY P, HOTTELART C, et al: Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis. Artif Organs 22:564-568, 1998
42. US RENAL DATA SYSTEM: USRDS 1999 Annual Data Report, Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999
43. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
44. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
45. BRAUN J, OLDENDORF M, MOSHAGE W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27(3):394-401, 1996
46. RIBEIRO S, RAMOS A, BRANDAO A, et al: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037-2040, 1998
47. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
48. WANG AY, WANG M, WOO J, et al: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol 14:159-168, 2003
49. LESKINEN Y, SALENIUS JP, LEHTIMAKI T, et al: The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: Requirements for diagnostics. Am J Kidney Dis 40:472-479, 2002
50. GOODMAN WG, LONDON G, AMANN K, et al: Vascular Calcification Work Group. Vascular calcification in chronic kidney disease. Am J Kidney Dis 43(3):572-579, 2004
51. MUCSI I, HERCZ G: Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 317:405-409, 1999
52. FOURNIER A, SAID S, GHAZALI A, et al: The clinical significance of adynamic bone disease in uremia. Adv Nephrol Necker Hosp 27:131-166, 1997
53. GUILLOT AP, HOOD VL, RUNGE CF, GENNARI FJ: The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 30:114-117, 1982
54. MORINIERE P, VINATIER I, WESTEEL PF, et al: Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 3:651-656, 1988
55. DELMEZ JA, KELBER J, NORWORD KY, et al: Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 49:163-167, 1996
56. JOY MS, FINN WF: LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96-107, 2003
57. GRAFF L, BURNEL D: Reduction of dietary phosphorus absorption by oral phosphorus binders. Res Commun Mol Pathol Pharmacol 90:389-401, 1995
58. HERGESELL O, RITZ E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863-867, 1999
59. KURODA S, KOMORI M, NAGAMATSU K, et al: Effect of iron as a new type of phosphate binder in hemodialysis patients. Nippon Jinzo Gakkai Shi 37:468-473, 1995
60. RITZ E, HERGESELL O: Compounds in development to combat hyperphosphataemia. Expert Opin Investig Drugs 10:2185-2190, 2001
61. YANG WC, YANG CS, HOU CC, et al: An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate. Nephrol Dial Transplant 17:265-270, 2002
62. CHERTOW GM, BURKE SK, LAZARUS JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29(1):66-71, 1997
63. SWEARINGEN RA, CHEN X, PETERSEN JS, et al: Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 20:195-201, 2002
64. CHERTOW GM, BURKE SK, DILLON MA, SLATOPOLSKY E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14:2907-2914, 1999
65. CHERTOW GM, BURKE SK, RAGGI P: Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
66. BRAUNLIN W, ZHOROV E, GUO A, et al: Bile acid binding to sevelamer HCl. Kidney Int 62:611-619, 2002
67. QUNIBI WY, HOOTKINS RE, MCDOWELL LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914-1926, 2004
68. SADEK T, MAZOUZ H, BAHLOUL H, et al: Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study. Nephrol Dial Transplant 8:582-588, 2003
69. BLEYER AJ, BURKE SK, DILLON M, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999
70. HERVAS JG, PRADOS D, CEREZO S: Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. Kidney Int (Suppl):S69-72, 2003
71. CHERTOW GM, BURKE SK, RAGGI P: Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
72. KATAI K, TANAKA H, TATSUMI S, et al: Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14:1195-1201, 1999
73. SHIMODA K, AKIBA T, MATSUSHIMA T, et al: Niceritrol decreases serum phosphate levels in chronic hemodialysis patients. Nippon Jinzo Gakkai Shi 40:1-7, 1998